Home › Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma clinical trials recruiting in the U.S.
35 studies for Esophageal Squamous Cell Carcinoma are recruiting participants at sites across the United States.
Cities with the most studies
- Arlington, VA16 studies
- Nashville, TN13 studies
- Houston, TX13 studies
- Los Angeles, CA12 studies
- Baldwin Park, CA10 studies
- New York City, NY9 studies
- West Valley City, UT7 studies
- San Antonio, TX7 studies
- Dallas, TX6 studies
- Orlando, FL6 studies
- Santa Monica, CA6 studies
- Queens, NY6 studies
- Austin, TX5 studies
- St. Louis, MO5 studies
- Boston, MA5 studies
- Irvine, CA5 studies
- Cleveland, OH5 studies
- Detroit, MI5 studies
- Fort Worth, TX5 studies
- Grand Rapids, MI5 studies
- Portland, OR4 studies
- Durham, NC4 studies
- Atlanta, GA4 studies
- Chicago, IL4 studies
- Pittsburgh, PA4 studies
- San Francisco, CA4 studies
- Rochester, MN3 studies
- Omaha, NE3 studies
- Fullerton, CA3 studies
- Orange, CA3 studies
- Seattle, WA3 studies
- Bridgeport, CT3 studies
- Philadelphia, PA3 studies
- New Haven, CT3 studies
- Irving, TX3 studies
- Coral Springs, FL3 studies
- Las Vegas, NV3 studies
- Greenville, SC3 studies
- Sarasota, FL3 studies
- Plantation, FL3 studies
By state
- Arizona7 studies
- California26 studies
- Colorado3 studies
- Connecticut4 studies
- Florida12 studies
- Georgia4 studies
- Illinois6 studies
- Massachusetts5 studies
- Michigan11 studies
- Minnesota5 studies
- Missouri6 studies
- Nebraska3 studies
- Nevada3 studies
- New Jersey6 studies
- New York15 studies
- North Carolina4 studies
- Ohio9 studies
- Oregon4 studies
- Pennsylvania8 studies
- South Carolina3 studies
- Tennessee13 studies
- Texas20 studies
- Utah7 studies
- Virginia16 studies
- Washington6 studies
Recently updated studies
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT06780111A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07405151A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07503808A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07090499CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07909031Study of XB010 in Subjects With Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06545331A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT07109726A Study of MGC026 in Participants With Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06242470A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06747585A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06644781A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT07730021A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT05914116A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT07554521Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT06084481A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT05563766A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 7, 2026 · NCT05319730Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06265285177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07189871A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07085091A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277413Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07229313A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07217171Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06535607A Study of IDP-001 in Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT07602842From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.